Benvenue Launches Kiva Armed With Favorable Study Results
This article was originally published in The Gray Sheet
Executive Summary
Benvenue Medical Inc. announced the launch of its Kiva VCF Treatment System for vertebral compression fractures in the spine March 24, along with favorable data announced at a meeting of the Society of Interventional Radiology.
You may also be interested in...
People Briefs: Calhoun Vision, Benvenue Medical, Urologix, Pentax
Calhoun Vision appoints CEO. Urologix, Benvenue Medical hire CFOs. Pentax Medical promotion.
Device/Diagnostics Quarterly Deal Statistics, Q2 2014
Device funding increased 123% to $1.6 billion in Q2, and M&A activity was overshadowed by Medtronic’s massive $47 billion acquisition of Covidien. Diagnostics fundraising dropped slightly to $522 million, and there were multiple takeovers of life sciences companies.
Benvenue Medical Touts Next-Generation Treatment For Vertebral Compression Fractures
At the recent CIRCE meeting, researchers presented positive clinical data comparing Benvenue Medical Inc.’s Kiva vertebral compression fracture system versus Medtronic’s market-leading Kyphon kyphoplasty system, providing a boost for Benvenue, which is awaiting FDA 510(k) clearance of its device.